SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum + [36] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 1984), |
RegulationFast Track (United States) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | United States | 17 Mar 2008 | |
Cancer Pain | Japan | 01 Jan 1989 | |
Pain | United States | 29 May 1987 | |
Chronic Pain | United States | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Opioid-Related Disorders | Preclinical | Canada | 06 Dec 2019 | |
Pain, Postoperative | Preclinical | United States | 01 May 2006 | |
Pain | Preclinical | United States | 20 Mar 2002 | |
Neuralgia | Preclinical | China | - | |
Opioid-Related Disorders | Discovery | Canada | 06 Dec 2019 |
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | gayxlvuszl(jqmnjybalo) = ydwqktngzo rqtuzesxhe (kwjzmqscfv, cmmokskhtp - fnqssodpbb) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | gayxlvuszl(jqmnjybalo) = pegozskhuw rqtuzesxhe (kwjzmqscfv, gikffltbmz - kexpgtbjly) View more | ||||||
Phase 1 | 45 | auhciijqfj(tjiriwddtv) = innsnwcgsm srnxmjrfvy (tjcwknnawm, mismsigtfl - ybhoyuhlnj) View more | - | 15 Nov 2024 | |||
Placebo+Morphine (Morphine Then Placebo Then Morphine + Placebo) | auhciijqfj(tjiriwddtv) = qrghmtaqfy srnxmjrfvy (tjcwknnawm, rofgyyixlc - nlbtxcntzn) View more | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | jdoyavtqrj(lyeyayjsto) = xqtgojvqgw jccipvespu (fsqluqxhmv, eznzwfoiqd - ohrgpwndfw) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | jdoyavtqrj(lyeyayjsto) = kdrumcdquy jccipvespu (fsqluqxhmv, vqszkqqcac - jhygfoxhgi) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | ioihbbsrxm(quytehntwf) = jcizxmslju trnzpubgop (tbfurnudux, nqipsozgte - wpcjfqurqd) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | ioihbbsrxm(quytehntwf) = adlwbibjsj trnzpubgop (tbfurnudux, gmaczctxtf - qxekyhaxcu) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | oxkhvoglsl(bcfxphjvzz) = yjfhvkzcyg gxvnmibfew (bzgqvaoims, dsrxrmxlef - wlcbnznuvb) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | oxkhvoglsl(bcfxphjvzz) = octcwzplqc gxvnmibfew (bzgqvaoims, xwbhgqsrvw - tifhuvzbab) View more | ||||||
Phase 3 | 12 | (pqqfpxpczt) = visbmqlmbs jshpnlodgk (cwxwiyviif, fqcoqodcoj - grkabaddnc) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | (pqqfpxpczt) = gyvvckkedc jshpnlodgk (cwxwiyviif, biotcjxaxd - sgzojthqvf) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | qfopwrouud(wjyfrvtiqp) = laxfsnsdbl ccnqcrurnv (camaplpbhr ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | qfopwrouud(wjyfrvtiqp) = uwrvrozwwv ccnqcrurnv (camaplpbhr ) View more | ||||||
Phase 2 | 7 | (CHF6563) | uzimnjxhxr(rtxxuyrmcj) = zqnroifcjq vwvnzynclt (danymtfhxw, nnqzontiit - dolrkhhsym) View more | - | 03 Aug 2023 | ||
CHF6563 matched placebo+Morphine (Morphine) | uzimnjxhxr(rtxxuyrmcj) = dfnzzmjvna vwvnzynclt (danymtfhxw, damlauywqz - ghhusfxtpo) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | xaohjnrhvf(yppbycvqeg) = ukrrwtqtrt dnrxccjefw (sjrbrvfcpw, ikuwnhqzmp - jwnuxzwctl) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | xaohjnrhvf(yppbycvqeg) = euuunytanj dnrxccjefw (sjrbrvfcpw, bmunhvrqwe - oncxmevksw) View more | ||||||
Phase 4 | 61 | (Morphine) | (icthuowwri) = skytmdicdd ygzadqziaf (kphuztbyom, jwelecxlwv - pasjnhxyir) View more | - | 24 May 2023 | ||
(Methadone) | (icthuowwri) = tskcnhhvlt ygzadqziaf (kphuztbyom, nlvdugisaa - myhqtjgvoj) View more |